NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

Search

Roche Holding AG

Slēgts

SektorsVeselības aprūpe

367.2 2.11

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

356.2

Max

367.2

Galvenie mērījumi

By Trading Economics

Ienākumi

1.8B

5.5B

Pārdošana

15B

31B

P/E

Sektora vidējais

22.556

121.746

Dividenžu ienesīgums

2.7

Peļņas marža

17.892

Darbinieki

103,249

EBITDA

1.5B

8B

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.70%

2.26%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1B

288B

Iepriekšējā atvēršanas cena

365.09

Iepriekšējā slēgšanas cena

367.2

Ziņu noskaņojums

By Acuity

67%

33%

310 / 352 Rangs Healthcare

Roche Holding AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. janv. 10:07 UTC

Peļņas

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

2026. g. 29. janv. 07:07 UTC

Peļņas

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

2025. g. 18. nov. 11:04 UTC

Galvenie tirgus virzītāji

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

2025. g. 23. okt. 09:32 UTC

Peļņas

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

2025. g. 23. okt. 05:54 UTC

Peļņas

Roche Raises Full-Year Earnings Outlook

2026. g. 29. janv. 11:40 UTC

Tirgus saruna
Peļņas

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

2026. g. 29. janv. 06:05 UTC

Peļņas

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

2026. g. 29. janv. 06:04 UTC

Peļņas

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

2026. g. 29. janv. 06:03 UTC

Peļņas

Roche Issues 2026 View

2026. g. 29. janv. 06:02 UTC

Peļņas

Analysts Saw 2025 Core EPS at CHF19.70

2026. g. 29. janv. 06:02 UTC

Peļņas

Roche: 2025 Core EPS CHF19.46

2026. g. 29. janv. 06:01 UTC

Peļņas

Analysts Had Seen 2025 Sales At CHF61.47B

2026. g. 29. janv. 06:01 UTC

Peļņas

Roche 2025 Sales CHF61.52B

2026. g. 28. janv. 11:22 UTC

Peļņas

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

2026. g. 27. janv. 11:31 UTC

Tirgus saruna

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

2026. g. 27. janv. 11:24 UTC

Tirgus saruna

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

2026. g. 27. janv. 09:30 UTC

Tirgus saruna

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

2026. g. 27. janv. 07:52 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Roche Obesity Study Data Look Encouraging -- Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026. g. 12. janv. 14:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Pharma Sector Can Spend Big on M&A -- Market Talk

2025. g. 22. dec. 08:48 UTC

Tirgus saruna

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

2025. g. 19. nov. 12:47 UTC

Tirgus saruna

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

2025. g. 10. nov. 12:16 UTC

Tirgus saruna
Peļņas

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

2025. g. 23. okt. 09:19 UTC

Tirgus saruna
Peļņas

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

2025. g. 23. okt. 09:11 UTC

Tirgus saruna
Peļņas

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

2025. g. 23. okt. 05:09 UTC

Peļņas

Roche 3Q Sales Up 6% At CER

2025. g. 23. okt. 05:07 UTC

Peļņas

Roche 3Q Sales CHF14.92B

2025. g. 23. okt. 05:07 UTC

Peļņas

Analysts Had Seen 3Q Sales At CHF15.17B

2025. g. 23. okt. 05:07 UTC

Peļņas

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

2025. g. 23. okt. 05:05 UTC

Peļņas

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Salīdzinājums

Cenas izmaiņa

Roche Holding AG Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

310 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat